TMPRSS2 and COVID-19: The serine protease inhibitor nafamostat is in clinical trials as a potential treatment for COVID-19, owing to its ability to inhibit TMPRSS2-mediated viral entry of SARS-CoV2 into lung epithelial cells [1, 2].